United Services Automobile Association trimmed its stake in Mirati Therapeutics Inc (NASDAQ:MRTX) by 4.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,826 shares of the biotechnology company’s stock after selling 338 shares during the period. United Services Automobile Association’s holdings in Mirati Therapeutics were worth $703,000 at the end of the most recent reporting period.
Several other hedge funds also recently modified their holdings of the stock. FMR LLC raised its stake in shares of Mirati Therapeutics by 109.7% in the 1st quarter. FMR LLC now owns 4,606,270 shares of the biotechnology company’s stock valued at $337,640,000 after acquiring an additional 2,409,882 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Mirati Therapeutics by 36.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,984,506 shares of the biotechnology company’s stock valued at $307,404,000 after acquiring an additional 802,468 shares in the last quarter. BlackRock Inc. raised its stake in shares of Mirati Therapeutics by 8.6% in the 2nd quarter. BlackRock Inc. now owns 2,536,034 shares of the biotechnology company’s stock valued at $261,211,000 after acquiring an additional 199,939 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Mirati Therapeutics by 47.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,206,144 shares of the biotechnology company’s stock valued at $124,233,000 after acquiring an additional 388,516 shares in the last quarter. Finally, Invesco Ltd. raised its stake in shares of Mirati Therapeutics by 329.7% in the 2nd quarter. Invesco Ltd. now owns 1,002,795 shares of the biotechnology company’s stock valued at $103,288,000 after acquiring an additional 769,429 shares in the last quarter.
In other news, Director Bruce L. A. Carter sold 3,000 shares of Mirati Therapeutics stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $89.24, for a total transaction of $267,720.00. Following the sale, the director now owns 3,000 shares of the company’s stock, valued at approximately $267,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael G. Grey sold 3,042 shares of Mirati Therapeutics stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $92.27, for a total value of $280,685.34. Following the sale, the director now directly owns 4,840 shares in the company, valued at approximately $446,586.80. The disclosure for this sale can be found here. Insiders have sold a total of 845,360 shares of company stock worth $82,651,250 in the last three months. 4.86% of the stock is owned by insiders.
MRTX opened at $76.93 on Friday. The firm has a market capitalization of $2.91 billion, a P/E ratio of -24.12 and a beta of 2.00. The stock’s 50 day moving average price is $83.35 and its two-hundred day moving average price is $84.95. Mirati Therapeutics Inc has a 12-month low of $28.50 and a 12-month high of $111.99.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.08). The firm had revenue of $0.58 million during the quarter. As a group, equities research analysts expect that Mirati Therapeutics Inc will post -5.09 EPS for the current year.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.
Featured Story: How is a price target determined?
Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics Inc (NASDAQ:MRTX).
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.